Key facts
- It has raised $14.2M; the latest was Later Stage VC ($14.2M) in Jan 2026.
- Notable investors include China State-owned Enterprise Mixed Ownership Reform Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Gwalrus Biomaterials
- ·The full record, as it builds
Funding rounds
No funding rounds for Gwalrus Biomaterials are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gwalrus Biomaterials
Manufacturer of bio-based materials designed to promote sustainable, low-carbon industrial applications. The company offers synthetic biology technology, integrated biomaterial production, and full industrial chain capabilities, enabling manufacturers across various industries, including packaging, textiles, agriculture, biomedicine, and consumer goods, to adopt environmentally friendly materials and reduce their carbon footprint.
- Sector
- Materials and Resources
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 38
- Website
- gwalrus.com/
- Ownership
- Privately Held (backing)
Gwalrus Biomaterials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gwalrus Biomaterials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gwalrus Biomaterials in its N-PORT filings yet. We sweep new filings monthly.